IP Library Granted Patent US 9,561,006
Granted Patent B2
US 9,561,006 · App. 13/662,456 · Granted Feb 7, 2017

Bayesian modeling of pre-transplant variables accurately predicts kidney graft survival

Inventors: Eric A. Elster (Kensington, MD); Doug Tadaki (Frederick, MD); Trevor S. Brown (Gaithersburg, MD); Rahul Jindal (Silver Spring, MD)
Assignee: The United States of America as represented by the Secretary of the Navy
A61B5/7267A61B5/201A61B5/4848A61B5/7275G06F19/322G06F19/345G06F19/3437
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,561,006
App. No.
13/662,456
Granted
Feb 7, 2017
Kind
B2
Abstract

An embodiment of the invention provides a method for determining a patient-specific probability of renal transplant survival. The method collects clinical parameters from a plurality of renal transplant donor and patient to create a training database. A fully unsupervised Bayesian Belief Network model is created using data from the training database; and, the fully unsupervised Bayesian Belief Network is validated. Clinical parameters are collected from an individual patient/donor; and, such clinical parameters are input into the fully unsupervised Bayesian Belief Network model via a graphical user interface. The patient-specific probability of disease is output from the fully unsupervised Bayesian Belief Network model and sent to the graphical user interface for use by a clinician in pre-operative organ matching. The fully unsupervised Bayesian Belief Network model is updated using the clinical parameters from the individual patient and the patient-specific probability of transplant survival.

Claims (12)

1. A method for determining a patient-specific probability of renal transplant survival, said method including:

a) collecting clinical parameters from a plurality of patients and donor to create a training database, the clinical parameters;

b) creating a fully unsupervised Bayesian Belief Network model using data from the training database;

c) validating the fully unsupervised Bayesian Belief Network model;

d) collecting the clinical parameters for an individual patient and an donor;

e) receiving the clinical parameters for the individual patient and an donor into the fully unsupervised Bayesian Belief Network model;

f) outputting the patient-specific probability of transplant survival from the fully unsupervised Bayesian Belief Network model to a graphical user interface for use by a clinician; and

g) updating the fully unsupervised Bayesian Belief Network model using the clinical parameters for the individual patient and for the donor, and the patient-specific probability of transplant survival.

2. The method according to claim 1 , wherein the patient clinical parameters include a plurality of the following: age of diabetes onset; age at time of transplant; Body Mass Index (BMI); indication of creatinine decline by 25% or more in the first 24 hours following transplant; the primary diagnosis; type of diabetes; dialysis type at time of listing; number of days on dialysis pre-transplant; an indication of return to dialysis with the first week following transplantation; length of graft survival; graft loss due to thrombosis; induction medication administered; type of transplantation procedure applied; use of maintenance or anti-rejection medications post-transplant; result of Human Leukocyte Antigen (HLA) testing; most recent serum creatinine prior to discharge following transplantation procedure; most recent absolute creatinine at time of listing; most recent Panel Reactive Antibody (PRA) in the USRDS; requirement of pretransplant dialysis; blood type; recurrent disease in graft; race; gender; serum creatinine at time of transplant; and drug treated systemic hypertension at time of listing.

3. The method according to claim 1 , wherein the donor clinical parameters include: cardiac arrest since neurological event that led to declaration of brain death; total cold ischemia time; blood type; age; BMI; cause of death; serum creatinine; history of diabetes; history of hypertension; any sue of cigarettes; indication of donation after cardiac death (DCD); drug use; race; gender; organ warm ischemic time for DCD; cocaine use specifically; use of perfusion pump; and the total warm ischemia and anastomotic time.

4. The method according to claim 1 , wherein said creating of the fully unsupervised Bayesian Belief Network model includes creating the fully unsupervised Bayesian Belief Network model without human-developed decision support rules.

5. The method according to claim 1 , further including estimating an accuracy of the patient-specific probability of transplant survival, the accuracy including at least one of model sensitivity, model specificity, positive and negative predictive values, and overall accuracy.

Continuity (6)
Continuation In Part 13083090 · Apr 8, 2011
Continuation In Part 13123406 · May 7, 2011
Continuation In Part 13083184 · Apr 8, 2011
Provisional Application 61553876 · Oct 31, 2011
Related Publication 20140122382A1 · May 1, 2014
Related Publication 20160206249A9 · Jul 21, 2016